{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:05:27Z","timestamp":1790719527075,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Temocillin is a 6\u03b1-methoxy derivative of ticarcillin that is resilient to ESBLs. Prospective data about its in vivo activity remain scarce. Our aims were: (i) to evaluate the activity of temocillin in a urinary tract infection (UTI) model due to ESBL-producing Escherichia coli and compare it with that of imipenem; and (ii) to define in vivo susceptibility breakpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Mice were infected with a susceptible E. coli CFT073-RR or its transconjugant (CFT073-RR Tc) harbouring a blaCTX-M-15-carrying plasmid, using an ascending UTI model. Therapeutic regimens were chosen in order to reproduce percentage of time of free drug concentrations above MIC (fT&amp;gt;MIC) obtained in humans with standard regimens of temocillin (200 mg\/kg every 2 h for 2 g every 12 h) or imipenem (100 mg\/kg every 2 h for 1 g every 8 h). Additional regimens of temocillin (200 mg\/kg every 4 and 6 h) with reduced fT&amp;gt;MIC were studied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MICs of temocillin and imipenem were 4\/8 and 0.5\/0.5 mg\/L, for CFT073-RR and CFT073-RR Tc, respectively. In vivo, when given every 2 h (fT&amp;gt;MIC\u200a=\u200a82% and 70%), temocillin was bactericidal and as effective as imipenem in kidneys against both strains without selecting resistant mutants. Temocillin remained active even when given every 4 h, generating an fT&amp;gt;MIC of 41% and 35%, which corresponded to a breakpoint of 16 mg\/L in humans with the standard regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our observations support the consideration of a standard regimen of temocillin as an alternative to carbapenems for the treatment of UTI due to CTX-M-producing E. coli strains with an MIC of 16 mg\/L or less.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dku542","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T03:38:37Z","timestamp":1420601917000},"page":"1466-1472","source":"Crossref","is-referenced-by-count":34,"title":["Activity of temocillin in a murine model of urinary tract infection due to <i>Escherichia coli<\/i> producing or not producing the ESBL CTX-M-15"],"prefix":"10.1093","volume":"70","author":[{"given":"J. F.","family":"Soubirou","sequence":"first","affiliation":[{"name":"1 \u00a0INSERM, IAME, UMR 1137, F-75018 Paris, France"},{"name":"2 \u00a0Universit\u00e9 Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cit\u00e9, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rossi","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, IAME, UMR 1137, F-75018 Paris, France"},{"name":"2 \u00a0Universit\u00e9 Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cit\u00e9, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Couffignal","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, IAME, UMR 1137, F-75018 Paris, France"},{"name":"2 \u00a0Universit\u00e9 Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cit\u00e9, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rupp\u00e9","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, IAME, UMR 1137, F-75018 Paris, France"},{"name":"2 \u00a0Universit\u00e9 Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cit\u00e9, F-75018 Paris, France"},{"name":"3 \u00a0AP-HP, Groupe Hospitalier Paris Nord Val de Seine, Laboratoire de Microbiologie, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chau","sequence":"additional","affiliation":[{"name":"2 \u00a0Universit\u00e9 Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cit\u00e9, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Massias","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, IAME, UMR 1137, F-75018 Paris, France"},{"name":"4 \u00a0AP-HP, Groupe Hospitalier Paris Nord Val de Seine, \u00a0Laboratoire de Pharmacologie, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lepeule","sequence":"additional","affiliation":[{"name":"5 \u00a0AP-HP, Groupe Hospitalier Paris Nord Val de Seine, Service de m\u00e9decine interne, F-92210 Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mentre","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, IAME, UMR 1137, F-75018 Paris, France"},{"name":"2 \u00a0Universit\u00e9 Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cit\u00e9, F-75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fantin","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, IAME, UMR 1137, F-75018 Paris, France"},{"name":"2 \u00a0Universit\u00e9 Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cit\u00e9, F-75018 Paris, France"},{"name":"5 \u00a0AP-HP, Groupe Hospitalier Paris Nord Val de Seine, Service de m\u00e9decine interne, F-92210 Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,1,5]]},"reference":[{"key":"2022020121022260800_DKU542C1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2022020121022260800_DKU542C2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dkm464","article-title":"Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15","volume":"61","author":"Nicolas-Chanoine","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"2022020121022260800_DKU542C3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/318850","article-title":"Urinary tract infections: disease panorama and challenges","volume":"183","author":"Stamm","year":"2001","journal-title":"J Infect Dis"},{"key":"2022020121022260800_DKU542C4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","article-title":"Infections with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices","volume":"70","author":"Pitout","year":"2010","journal-title":"Drugs"},{"key":"2022020121022260800_DKU542C5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2022020121022260800_DKU542C6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijantimicag.2008.06.012","article-title":"Emergence of imipenem resistance in clinical Escherichia coli during therapy","volume":"32","author":"Oteo","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2022020121022260800_DKU542C7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022020121022260800_DKU542C8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022020121022260800_DKU542C9","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkl043","article-title":"Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England","volume":"57","author":"Livermore","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2022020121022260800_DKU542C10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10096-007-0370-9","article-title":"In vitro activity of temocillin against prevalent extended-spectrum \u03b2-lactamases producing Enterobacteriaceae from Belgian intensive care units","volume":"26","author":"Glupczynski","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022020121022260800_DKU542C11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1179\/acb.2001.053","article-title":"Comparative in vitro activity of temocillin and other antimicrobial agents against Enterobacteriaceae isolated from patients admitted to five Belgian hospitals","volume":"56","author":"Vanhoof","year":"2001","journal-title":"Acta Clin Belg"},{"key":"2022020121022260800_DKU542C12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/dkm179","article-title":"Temocillin susceptibility by BSAC methodology","volume":"60","author":"Andrews","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2022020121022260800_DKU542C13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF02148656","article-title":"Interpretive criteria for temocillin disk diffusion susceptibility testing","volume":"4","author":"Fuchs","year":"1985","journal-title":"Eur J Clin Microbiol"},{"key":"2022020121022260800_DKU542C14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/dkp208","article-title":"Clinical efficacy of temocillin","volume":"64","author":"Gupta","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022020121022260800_DKU542C15","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022020121022260800_DKU542C16","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.06233-11","article-title":"Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum \u03b2-lactamase","volume":"56","author":"Lepeule","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020121022260800_DKU542C17","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/jcm.35.6.1521-1525.1997","article-title":"Random amplification of polymorphic DNA reveals serotype-specific clonal clusters among enterotoxigenic Escherichia coli strains isolated from humans","volume":"35","author":"Pacheco","year":"1997","journal-title":"J Clin Microbiol"},{"key":"2022020121022260800_DKU542C18","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1128\/AAC.00150-06","article-title":"Clonal dissemination of a CTX-M-15 \u03b2-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui","volume":"50","author":"Lavollay","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020121022260800_DKU542C19","volume-title":"Performance Standards for Antimicrobial Susceptibility testing: Fifteenth Informational Supplement M100-S15","author":"Clinical and Laboratory Standards Institute","year":"2005"},{"key":"2022020121022260800_DKU542C20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/AAC.18.5.699","article-title":"Method of reliable determination of minimal lethal antibiotic concentrations","volume":"18","author":"Pearson","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020121022260800_DKU542C21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 5","key":"2022020121022260800_DKU542C22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003495-198500295-00020","article-title":"Pharmacokinetics of temocillin in volunteers","volume":"29","author":"Hampel","year":"1985","journal-title":"Drugs"},{"key":"2022020121022260800_DKU542C23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/AAC.16.5.592","article-title":"Pharmacokinetics of cefotaxime","volume":"16","author":"Fu","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020121022260800_DKU542C24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models","volume":"159","author":"Leggett","year":"1989","journal-title":"J Infect Dis"},{"key":"2022020121022260800_DKU542C25","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","article-title":"Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model","volume":"51","author":"Samson","year":"2006","journal-title":"Comput Stat Data Anal"},{"key":"2022020121022260800_DKU542C26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0924-8579(02)00105-X","article-title":"Correlation between pharmacokinetic\/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection","volume":"9","author":"Frimodt-M\u00f8ller","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"2022020121022260800_DKU542C27","first-page":"257","article-title":"Temocillin","volume-title":"Antibiotic and Chemotherapy","author":"Bush","year":"2003"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/5\/1466\/42355276\/jac_70_5_1466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/5\/1466\/42355276\/jac_70_5_1466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:11:30Z","timestamp":1643749890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/5\/1466\/689550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,5]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,1,5]]},"published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku542","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,5]]},"published":{"date-parts":[[2015,1,5]]}}}